Somatostatinoma is a very rare neuroendocrine tumor that secretes somatostatin and classically presents with the triad of diabetes, gallstones, and steatorrhea. Many tumors are found incidentally; treatment is surgical when feasible, with medical therapy for advanced disease.
What Somatostatinoma Is
Somatostatinomas arise from somatostatin-producing D cells, which are scattered through the pancreas, duodenum, and other parts of the gastrointestinal tract. Annual incidence is on the order of 1 case per 40 million people — among the rarest functional neuroendocrine tumors. They occur most often between the fourth and sixth decades.
- ~55 to 60 percent pancreatic (most often the head)
- ~40 to 45 percent duodenal or periampullary
- Rarer sites: jejunum, ileum, cystic duct, ampulla of Vater
- Most sporadic; associations with MEN1, neurofibromatosis type 1 (NF1), and von Hippel-Lindau syndrome are recognized — periampullary somatostatinomas in NF1 are characteristic
Why Somatostatinoma Causes Diabetes
Somatostatin is an inhibitory hormone. Excess somatostatin produces a recognizable triad through its actions on multiple targets:
- Inhibition of pancreatic insulin secretion — causing hyperglycemia and diabetes
- Inhibition of pancreatic glucagon secretion — modulating but not preventing hyperglycemia
- Inhibition of cholecystokinin and gallbladder contraction — causing biliary stasis and cholelithiasis
- Inhibition of pancreatic exocrine enzymes — causing fat malabsorption and steatorrhea
- Inhibition of gastric acid secretion — causing achlorhydria in some patients
- Inhibition of intestinal motility — causing diarrhea or constipation
About 75 percent of patients have mild diabetes. The diabetes is usually well controlled with oral agents because residual beta-cell function is preserved. For broader context, see complications and related conditions.
Clinical Presentation
| Feature | Pancreatic Somatostatinoma | Duodenal Somatostatinoma |
|---|---|---|
| Diabetes | Common (~75 percent) | Less common |
| Cholelithiasis | Common (~60 to 70 percent) | Less common |
| Steatorrhea | Common (~40 to 50 percent) | Uncommon |
| Weight loss | Common | Less common |
| Hypochlorhydria | Sometimes | Sometimes |
| Anemia | Sometimes | Less common |
| Presentation | Functional syndrome | Often incidental — biliary obstruction, GI bleeding, ampullary mass |
| Association with NF1 | Rare | Strong |
How Clinicians Diagnose Somatostatinoma
- Fasting plasma somatostatin — often markedly elevated (multiples of the upper limit of normal); test availability is limited and reference ranges vary
- Chromogranin A — usually elevated in well-differentiated NETs
- Glucose and A1C — see A1C levels
- Lipid panel and fecal fat testing if steatorrhea is suspected
- Abdominal ultrasound for gallstones and gallbladder evaluation
- Multiphase pancreas-protocol CT or MRI
- Endoscopic ultrasound with biopsy for small or uncertain pancreatic lesions
- Upper endoscopy with biopsy for duodenal or ampullary lesions
- 68Ga-DOTATATE PET/CT for staging and detection of metastases
- Genetic testing for MEN1 and NF1 in appropriate clinical contexts
Histology
Most somatostatinomas are well-differentiated neuroendocrine tumors. Pancreatic tumors tend to be larger and more aggressive; duodenal tumors are smaller and often have characteristic “psammoma bodies” on histology, especially in NF1-associated cases. Immunohistochemistry confirms expression of somatostatin and neuroendocrine markers (chromogranin A, synaptophysin, CD56). Tumor grade (Ki-67 index, mitotic count) is critical to staging and management.
Differential Diagnosis
- Other functional pancreatic neuroendocrine tumors (insulinoma, gastrinoma, VIPoma, glucagonoma)
- Non-functional pancreatic neuroendocrine tumor
- Pancreatic adenocarcinoma
- Ampullary adenocarcinoma
- Periampullary somatostatin-cell hyperplasia in NF1
- Routine type 2 diabetes with incidental cholelithiasis
- Celiac disease or other malabsorption syndromes
Treatment
Management is multidisciplinary and depends on tumor location, stage, and grade.
- Surgical resection — first-line for localized disease; Whipple (pancreaticoduodenectomy) for pancreatic head and periampullary tumors, distal pancreatectomy for body and tail lesions; segmental duodenal resection for selected small duodenal tumors
- Cholecystectomy — often performed at the time of pancreatic surgery, particularly if long-term somatostatin analog therapy is anticipated (further reduces gallbladder contractility)
- Somatostatin analogs — octreotide LAR, lanreotide depot — surprisingly effective despite the underlying somatostatin excess; reduce tumor growth and symptoms
- Peptide receptor radionuclide therapy (PRRT) — 177Lu-DOTATATE for somatostatin-receptor-positive metastatic disease
- Targeted therapy — everolimus, sunitinib for pancreatic NETs
- Chemotherapy — temozolomide-based regimens, streptozotocin combinations
- Liver-directed therapy — surgical debulking, ablation, transarterial embolization for hepatic metastases
- Supportive care — pancreatic enzyme replacement for steatorrhea, ursodeoxycholic acid for prevention of gallstones with somatostatin analog therapy, diabetes management, nutrition support
Diabetes Management in Somatostatinoma
- Most patients are well controlled with metformin and lifestyle measures — see treatment
- Insulin may be required around surgery or for poorly controlled patients
- Monitor for malabsorption-related nutritional deficiencies — see diet and nutrition
- Adjust diabetes medications carefully when starting or stopping somatostatin analogs, which can change glucose patterns
- Address fat-soluble vitamin deficiencies in patients with steatorrhea
Associated Syndromes
| Syndrome | Genes | Notes |
|---|---|---|
| Neurofibromatosis type 1 (NF1) | NF1 | Strongly associated with periampullary somatostatinoma; cafe-au-lait spots, neurofibromas |
| MEN1 | MEN1 | Pancreatic NETs, pituitary adenomas, primary hyperparathyroidism |
| von Hippel-Lindau | VHL | Pancreatic NETs, hemangioblastomas, renal cell carcinoma, pheochromocytoma |
| Tuberous sclerosis complex | TSC1, TSC2 | Occasional pancreatic NETs |
Prognosis
Outcomes vary widely. Small, well-differentiated, completely resected tumors carry a favorable prognosis. Larger, higher-grade, or metastatic tumors have a more variable course. Modern multimodal therapy with somatostatin analogs, PRRT, liver-directed therapy, and targeted agents has substantially extended survival for patients with advanced disease. Surveillance continues lifelong because of the risk of late recurrence and, in hereditary syndromes, additional tumors.
When to See a Doctor
- New mild diabetes accompanied by unexplained weight loss and steatorrhea
- Symptomatic gallstones with concurrent diabetes and malabsorption
- Pancreatic or duodenal mass found on imaging
- Personal or family history of NF1, MEN1, or VHL
- Painless jaundice with a periampullary lesion
- Persistent diarrhea or fat malabsorption with no obvious cause
The Bottom Line
Somatostatinoma is among the rarest functional neuroendocrine tumors. It classically causes mild diabetes, gallstones, and steatorrhea, reflecting somatostatin’s broad inhibitory actions. Pancreatic tumors typically present with the full syndrome, while duodenal and ampullary tumors are often found incidentally. Treatment is surgical when feasible, with somatostatin analogs, PRRT, and other systemic therapies for advanced disease. Talk to your doctor and consider endocrinology and oncology referral if your symptoms suggest a neuroendocrine tumor.
